Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Adaptive Phage Therapeutics
22 Firstfield Rd., Suite 125
Gaithersburg, MD 20878
Phone: 844-972-0500
http://www.aphage.com/

Adaptive Phage Therapeutics, Inc. (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. APT's core asset is a large and continually expanding phage library (PhageBank) deployed with a companion diagnostic to achieve rapid response and cost-effective therapy for otherwise recalcitrant bacterial infections. The technology was developed by the biodefense program of U.S. Dept of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under the FDA emergency Investigational New Drug (eIND) allowance, PhageBank therapy has been used to treat approximately 20 critically ill patients in which standard-of-care antibiotics has failed.

Key Contact
Name
Greg Merril
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
10/07/19 $7,000,000 Alexandria Venture Investments
undisclosed


Featured Reading